Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNA11 | P29992 | 8/20 | 1.00 |
| ▸ | GNAQ | P50148 | 3/20 | 1.00 |
| ▸ | ELANE | P08246 | 4/20 | 0.34 |
| ▸ | HTRA1 | Q92743 | 5/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
| ▸ | FKBP1B | P68106 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14361129 | 1.00 | GNA11 (1.00) | GNA11GNAQELANEHTRA1GHSR | |
| SCHEMBL26118416 | 1.00 | GNA11 (1.00) | GNA11GNAQELANEHTRA1GHSR | |
| SCHEMBL22139625 | 0.96 | GNA11 (0.93) | GNA11GNAQELANEHTRA1FKBP1B | |
| SCHEMBL29587750 | 0.96 | GNA11 (0.93) | GNA11GNAQELANEHTRA1 | |
| SCHEMBL29799481 | 0.96 | GNA11 (0.92) | GNA11GNAQELANEHTRA1GHSR | |
| SCHEMBL29884447 | 0.95 | GNA11 (0.90) | GNA11GNAQELANEHTRA1 | |
| SCHEMBL29540174 | 0.95 | GNA11 (0.90) | GNA11GNAQELANEGHSRFKBP1B | |
| SCHEMBL22133305 | 0.95 | GNA11 (0.90) | GNA11GNAQELANEHTRA1GHSR | |
| SCHEMBL29393036 | 0.94 | GNA11 (0.89) | GNA11GNAQELANEHTRA1 | |
| SCHEMBL22133302 | 0.93 | GNA11 (0.86) | GNA11GNAQELANEHTRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177478-A1 | G ALPHA Q/11 INHIBITORS FOR USE AS AN ANALGESIC | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-06-05 | — | — | US | claimed |
| WO-2023192233-A1 | G ALPHA Q/11 INHIBITORS FOR USE AS AN ANALGESIC | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-05 | — | — | WO | claimed |
| US-20230130103-A1 | TARGETED PHARMACOLOGICAL THERAPEUTICS IN UVEAL MELANOMA | WASHINGTON UNIVERSITY | 2023-04-27 | — | — | US | claimed |
| CN-122036730-A | Gαq/11 protein inhibitor with purine skeleton, and preparation method and application thereof | 中山大学 | 2026-05-15 | — | — | CN | disclosed |
| US-12612442-B2 | G12-specific designer receptor exclusively activated by designer drugs | CELL NETWORKS GMBH (DE) | 2026-04-28 | — | — | US | disclosed |
| WO-2025245193-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF MUTANT GNAQ AND GNA11 | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250206782-A1 | BIOLOGICAL POLYMERS | RES & INNOVATION UK (GB) | 2025-06-26 | — | — | US | disclosed |
| US-20250177478-A1 | G ALPHA Q/11 INHIBITORS FOR USE AS AN ANALGESIC | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-06-05 | — | — | US | disclosed |
| CN-116492348-B | Application of HTR2B gene targeting compound in preparation of medicines for treating tumors | 上海交通大学医学院附属瑞金医院 | 2025-03-25 | — | — | CN | disclosed |
| US-20250032577-A1 | OPTOGENETIC VISUAL RESTORATION USING LIGHT-SENSITIVE GQ-COUPLED NEUROPSIN (OPSIN 5) | GENANS BIOTECHNOLOGY CO., LTD (CN) | 2025-01-30 | — | — | US | disclosed |
| US-20250011391-A1 | ULTRA LIGHT-SENSITIVE NEUROPSIN-BASED OPTOGENETIC TOOL FOR ACTIVATING G q-COUPLED SIGNALING AND/OR ACTIVATING CELLS | GENANS BIOTECHNOLOGY CO., LTD (CN) | 2025-01-09 | — | — | US | disclosed |
| US-11306122-B2 | Compositions and methods of inhibiting the binding of plasma IgG autoantibodies to serotonin 2A receptor | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3976639-A1 | METHOD AND SYSTEM FOR PREDICTING COUPLING PROBABILITIES OF G-PROTEIN COUPLED RECEPTORS WITH G-PROTEINS | Russell, Robert Bruce (DE) | 2022-04-06 | — | — | EP | disclosed |
| CN-112480122-B | Tetrahydroimidazo [1,2-a ] pyrazine compound, composition, preparation method and application thereof | 中山大学 | 2022-03-22 | — | — | CN | disclosed |
| US-20200282015-A1 | TARGETED PHARMACOLOGICAL THERAPEUTICS IN UVEAL MELANOMA | WASHINGTON UNIVERSITY | 2020-09-10 | — | — | US | disclosed |
| US-20200197528-A1 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2020-06-25 | — | — | US | disclosed |
| WO-2020128612-A2 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| US-8889615-B2 | Methods for promoting epithelialization and healing of chronic wounds | NEW YORK UNIVERSITY (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889615-B2 | Methods for promoting epithelialization and healing of chronic wounds | NEW YORK UNIVERSITY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120289463-A1 | Compositions and Methods for Promoting Epithelialization and Wound Closure | NEW YORK UNIVERSITY (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177478-A1 | G ALPHA Q/11 INHIBITORS FOR USE AS AN ANALGESIC | OPRK1, OPRD1, OPRL1 | GNA11 35/4885GNAQ 8/4885ELANE 3887/4885 |
| US-20120289463-A1 | Compositions and Methods for Promoting Epithelialization and Wound Closure | GSK3B, GSK3A, GSKIP | GNA11 3984/4885GNAQ 2827/4885ELANE 484/4885 |
| US-20230130103-A1 | TARGETED PHARMACOLOGICAL THERAPEUTICS IN UVEAL MELANOMA | MC1R, GNAQ, MITF | GNA11 363/4885GNAQ 2/4885ELANE 4471/4885 |
| US-20250206782-A1 | BIOLOGICAL POLYMERS | NSUN3, AARS1, TARBP1 | GNA11 2164/4885GNAQ 4164/4885ELANE 2497/4885 |
| US-20200282015-A1 | TARGETED PHARMACOLOGICAL THERAPEUTICS IN UVEAL MELANOMA | MC1R, MITF, PRKACA | GNA11 944/4885GNAQ 4/4885ELANE 4478/4885 |
| US-20200197528-A1 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | GNA15, GNA11, EEA1 | GNA11 2/4885GNAQ 5/4885ELANE 1984/4885 |
| US-12612442-B2 | G12-specific designer receptor exclusively activated by designer drugs | RGS12, GNG2, GNAI1 | GNA11 32/4885GNAQ 15/4885ELANE 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.